Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 9.12
(-0.44%)
CNY 9.12
(-0.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 367.7 Million CNY | 16.8% |
| 2022 | 259.41 Million CNY | 12.9% |
| 2021 | 229.76 Million CNY | 34.92% |
| 2020 | 170.29 Million CNY | -2.07% |
| 2019 | 173.89 Million CNY | -2.27% |
| 2018 | 177.92 Million CNY | 15.21% |
| 2017 | 154.44 Million CNY | 9.08% |
| 2016 | 141.59 Million CNY | 68.17% |
| 2015 | 84.19 Million CNY | 20.8% |
| 2014 | 69.7 Million CNY | 23.65% |
| 2013 | 56.36 Million CNY | 29.49% |
| 2012 | 43.53 Million CNY | 7.74% |
| 2011 | 40.4 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 58.05 Million CNY | 90.36% |
| 2024 Q1 | 40.35 Million CNY | -59.82% |
| 2024 Q2 | 35.38 Million CNY | -12.31% |
| 2023 Q3 | 71.49 Million CNY | 5.57% |
| 2023 FY | 302.99 Million CNY | 16.8% |
| 2023 Q1 | 63.35 Million CNY | -6.63% |
| 2023 Q4 | 100.42 Million CNY | 40.46% |
| 2023 Q2 | 67.72 Million CNY | 6.89% |
| 2022 Q2 | 62.24 Million CNY | 0.58% |
| 2022 Q3 | 67.43 Million CNY | 8.34% |
| 2022 Q4 | 67.85 Million CNY | 0.62% |
| 2022 FY | 259.41 Million CNY | 12.9% |
| 2022 Q1 | 61.88 Million CNY | -21.35% |
| 2021 Q1 | 50.91 Million CNY | -24.08% |
| 2021 Q2 | 37.34 Million CNY | -26.65% |
| 2021 Q4 | 78.68 Million CNY | 25.24% |
| 2021 FY | 229.76 Million CNY | 34.92% |
| 2021 Q3 | 62.82 Million CNY | 68.23% |
| 2020 Q3 | 25 Million CNY | -23.47% |
| 2020 Q1 | 45.53 Million CNY | 27.06% |
| 2020 Q4 | 67.06 Million CNY | 168.17% |
| 2020 FY | 170.29 Million CNY | -2.07% |
| 2020 Q2 | 32.67 Million CNY | -28.24% |
| 2019 Q1 | 37.2 Million CNY | -2.99% |
| 2019 Q4 | 35.84 Million CNY | -28.04% |
| 2019 FY | 173.89 Million CNY | -2.27% |
| 2019 Q3 | 49.8 Million CNY | -2.42% |
| 2019 Q2 | 51.04 Million CNY | 37.21% |
| 2018 Q3 | 51.4 Million CNY | -0.66% |
| 2018 FY | 177.92 Million CNY | 15.21% |
| 2018 Q4 | 38.34 Million CNY | -25.41% |
| 2018 Q2 | 51.75 Million CNY | 42.1% |
| 2018 Q1 | 36.42 Million CNY | -30.12% |
| 2017 Q3 | 32.86 Million CNY | -12.66% |
| 2017 Q2 | 37.62 Million CNY | 18.2% |
| 2017 Q4 | 52.11 Million CNY | 58.59% |
| 2017 FY | 154.44 Million CNY | 9.08% |
| 2017 Q1 | 31.83 Million CNY | -30.74% |
| 2016 FY | 141.59 Million CNY | 68.17% |
| 2016 Q1 | 25.47 Million CNY | -4.24% |
| 2016 Q3 | 38.58 Million CNY | 22.23% |
| 2016 Q4 | 45.96 Million CNY | 19.12% |
| 2016 Q2 | 31.56 Million CNY | 23.93% |
| 2015 Q2 | 21.59 Million CNY | 36.11% |
| 2015 Q4 | 26.6 Million CNY | 32.15% |
| 2015 Q3 | 20.12 Million CNY | -6.8% |
| 2015 Q1 | 15.86 Million CNY | -21.56% |
| 2015 FY | 84.19 Million CNY | 20.8% |
| 2014 FY | 69.7 Million CNY | 23.65% |
| 2014 Q1 | 13.6 Million CNY | 0.0% |
| 2014 Q4 | 20.23 Million CNY | 0.0% |
| 2013 FY | 56.36 Million CNY | 29.49% |
| 2012 FY | 43.53 Million CNY | 7.74% |
| 2011 FY | 40.4 Million CNY | 0.0% |